Literature DB >> 8976262

Do close but negative margins in radical prostatectomy specimens increase the risk of postoperative progression?

J I Epstein1, J Sauvageot.   

Abstract

PURPOSE: When tumor extends close to the margin of resection yet does not extend to the inked edge of the gland, it is unclear whether patients have an adverse prognosis compared to cases with greater distance between the tumor and margin.
MATERIALS AND METHODS: Among radical prostatectomy specimens with negative margins the distance between the most peripheral tumor and the surgical margin of resection was measured in 52 cases with and 49 without progression. All patients had clinically confined disease (stages T1 or T2) with subsequent progression or a minimum 5-year followup without evidence of disease. No patient received preoperative or postoperative radiotherapy or hormonal therapy until progression occurred. All men underwent a postoperative serum prostate specific antigen test to evaluate progression. Seminal vesicles and lymph nodes were pathologically free of tumor. All prostates were serially sectioned, completely embedded and assessable regarding margins of resection.
RESULTS: Patients with progression were no more likely to have tumor close to the margin than those without progression. In a regression analysis analyzing the effect of Gleason score, distance between tumor and margin, location of closest margin and pathological stage as related to progression, only grade was predictive of progression (p < 0.00001).
CONCLUSIONS: It is not necessary for pathologists to designate these margins as close, since biologically this finding has no significance. Furthermore, physicians who are involved in treatment of patients after radical prostatectomy for prostate cancer should not alter therapy depending on whether margins are reported as close.

Entities:  

Mesh:

Year:  1997        PMID: 8976262

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911).

Authors:  Theodorus H van der Kwast; Laurence Collette; Hein Van Poppel; Paul Van Cangh; Kris Vekemans; Luigi DaPozzo; Jean-François Bosset; Karl H Kurth; Fritz H Schröder; Michel Bolla
Journal:  Virchows Arch       Date:  2006-08-29       Impact factor: 4.064

2.  Randomized trial comparing an anterograde versus a retrograde approach to open radical prostatectomy: results in terms of positive margin rate.

Authors:  Alessandro Sciarra; Cristiano Cristini; Magnus Von Heland; Stefano Salciccia; Vincenzo Gentile
Journal:  Can Urol Assoc J       Date:  2010-06       Impact factor: 1.862

3.  Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence.

Authors:  Jason P Izard; Lawrence D True; Philip May; William J Ellis; Paul H Lange; Bruce Dalkin; Daniel W Lin; Rodney A Schmidt; Jonathan L Wright
Journal:  Am J Surg Pathol       Date:  2014-03       Impact factor: 6.394

4.  Frequency of positive surgical margin at prostatectomy and its effect on patient outcome.

Authors:  Kenneth A Iczkowski; M Scott Lucia
Journal:  Prostate Cancer       Date:  2011-06-09

5.  Determinants and effects of positive surgical margins after prostatectomy on prostate cancer mortality: a population-based study.

Authors:  Valesca P Retèl; Christine Bouchardy; Massimo Usel; Isabelle Neyroud-Caspar; Franz Schmidlin; Gregory Wirth; Christophe Iselin; Raymond Miralbell; Elisabetta Rapiti
Journal:  BMC Urol       Date:  2014-11-05       Impact factor: 2.264

6.  Factors affecting biochemical recurrence of prostate cancer after radical prostatectomy in patients with positive and negative surgical margin.

Authors:  Serdar Celik; Anıl Eker; İbrahim Halil Bozkurt; Deniz Bolat; İsmail Basmacı; Ertuğrul Şefik; Tansu Değirmenci; Bülent Günlüsoy
Journal:  Prostate Int       Date:  2020-09-17

Review 7.  Radical or Not-So-Radical Prostatectomy: Do Surgical Margins Matter?

Authors:  Ioanna Maria Grypari; Vasiliki Zolota; Vasiliki Tzelepi
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.